GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (FRA:GXE) » Definitions » EPS (Diluted)

Galapagos NV (FRA:GXE) EPS (Diluted) : €-2.58 (TTM As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV EPS (Diluted)?

Galapagos NV's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was €-2.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-2.58.

Galapagos NV's EPS (Basic) for the three months ended in Mar. 2025 was €-2.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was €-2.58.

Galapagos NV's EPS without NRI for the three months ended in Mar. 2025 was €-2.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was €-3.32.

During the past 3 years, the average EPS without NRIGrowth Rate was 22.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Galapagos NV's highest 3-Year average EPS without NRI Growth Rate was 71.10% per year. The lowest was -214.70% per year. And the median was -3.75% per year.


Galapagos NV EPS (Diluted) Historical Data

The historical data trend for Galapagos NV's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV EPS (Diluted) Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.69 -1.58 -3.32 3.21 1.12

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 0.14 -0.77 0.38 -2.33

Competitive Comparison of Galapagos NV's EPS (Diluted)

For the Biotechnology subindustry, Galapagos NV's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's PE Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's PE Ratio falls into.


;
;

Galapagos NV EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Galapagos NV's Diluted EPS for the fiscal year that ended in Dec. 2024 is calculated as

Diluted EPS (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(74.082-0)/65.897
=1.12

Galapagos NV's Diluted EPS for the quarter that ended in Mar. 2025 is calculated as

Diluted EPS (Q: Mar. 2025 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-153.403-0)/65.838
=-2.33

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV  (FRA:GXE) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Galapagos NV EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Galapagos NV's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines